Monster Beverage vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
US energy drink leader with $7.5B FY2024 revenue; Coca-Cola strategic partner (16.7% stake + global distribution); Bang acquisition 2023; competes with Celsius's fitness-focused challenger rise.
About
Monster Beverage Corporation is the world's leading energy drink company by market share in the United States, founded in 1935 as Hansen's Natural and rebranded to Monster Beverage in 2012, headquartered in Corona, California and trading on Nasdaq (MNST). The company generated approximately $7.5 billion in net sales for FY2024 under co-CEOs Hilton Schlosberg and Rob Sacks, with Monster Energy remaining the best-selling energy drink in the U.S. and the second globally behind Red Bull. A strategic partnership with Coca-Cola, which acquired a 16.7% stake in Monster in 2015 for approximately $2.15 billion and provides Monster with Coca-Cola's global distribution infrastructure, has been the foundational driver of Monster's international expansion across more than 150 countries.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.